Lokal fortgeschrittene Kopf-Hals-Tumoren: Therapiekonzepte und neue Ansätze

Lokal fortgeschrittene Kopf-Hals-Tumoren stellen aufgrund ihrer oft kritischen Lage bzgl. Funktionalität und Lebensqualität ein therapeutisches Problem dar, welches einer engen interdisziplinären Zusammenarbeit bedarf. Im folgenden Artikel möchten wir den Lesern eine Übersicht über die aktuellen Therapieprinzipien, über aktuelle radioonkologische und operative Technik sowie über den aktuellen Stand zur Immuntherapie im kurativen Setting geben.

Schlüsselwörter

Plattenepithelkarzinom - Kopf-Hals-Tumore - Strahlentherapie

• Literatur

• 1 Jansen L, Moratin J, Waldmann A. et al. Oral and pharyngeal cancer: incidence, mortality, and survival in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021; 64 (08) 941-950
• 2 Johnson DE, Burtness B, Leemans CR. et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020; 6 (01) 92
• 3 Lassen P, Primdahl H, Johansen J. et al. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiother Oncol 2014; 113 (03) 310-316
• 4 Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11 (01) 9-22
• 5 S3-Leitlinie Diagnostik und Therapie des Mundhöhlenkarzinoms. 2021
• 6 Robbins KT, Clayman G, Levine PA. et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg 2002; 128 (07) 751-758
• 7 S3-Leitlinie Diagnostik, Therapie und Nachsorge des Larynxkarzinoms. AWMF-Registernummer: 017/076OL. 2019
• 8 Ribassin-Majed L, Marguet S, Lee AWM. et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. J Clin Oncol 2017; 35 (05) 498-505
• 9 Xu H, Lu L, Lu T. et al. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma. Head Neck 2021; 43 (09) 2602-2610
• 10 Lacas B, Carmel A, Landais C. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021; 156: 281-293
• 11 van der Laan HP, van der Schaaf A, Van den Bosch L. et al. Quality of life and toxicity guided treatment plan optimisation for head and neck cancer. Radiother Oncol 2021; 162: 85-90
• 12 Gregoire V, Guckenberger M, Haustermans K. et al. Image guidance in radiation therapy for better cure of cancer. Mol Oncol 2020; 14 (07) 1470-1491
• 13 Linge A, Lohaus F, Lock S. et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2016; 121 (03) 364-373
• 14 Langendijk JA, Hoebers FJP, de Jong MA. et al. National Protocol for Model-Based Selection for Proton Therapy in Head and Neck Cancer. Int J Part Ther 2021; 8 (01) 354-365
• 15 McDonald BA, Vedam S, Yang J. et al. Initial Feasibility and Clinical Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation. Int J Radiat Oncol Biol Phys 2021; 109 (05) 1606-1618
• 16 Böke S, Gani C, Thorwarth D, et al. MR-geführte Dosiseskalation bei Kopf-Hals-Tumoren. Forum 2022; 37(01). .
• 17 Fu S, Li Y, Han Y. et al. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial. Int J Radiat Oncol Biol Phys 2022; 113 (01) 101-113
• 18 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
• 19 Fasano M, Corte CMD, Liello RD. et al. Immunotherapy for head and neck cancer: Present and future. Crit Rev Oncol Hematol 2022; 174: 103679
• 20 Lee NY, Ferris RL, Psyrri A. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2021; 22 (04) 450-462
• 21 Hecht M, Fietkau R, Gaipl US. Definitive chemoradiotherapy of locally advanced head and neck cancer in combination with immune checkpoint inhibition-new concepts required. Strahlenther Onkol 2022; 198 (01) 83-85
• 22 Antonia SJ, Villegas A, Daniel D. et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379 (24) 2342-2350